Follow
Roger S. Lo, MD., PhD
Roger S. Lo, MD., PhD
Professor of Medicine, Molecular and Medical Pharmacology
Verified email at mednet.ucla.edu
Title
Cited by
Cited by
Year
TGFβ signaling in growth control, cancer, and heritable disorders
J Massagué, SW Blain, RS Lo
Cell 103 (2), 295-309, 2000
32502000
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
29442016
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
29132016
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation
R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ...
Nature 468 (7326), 973-977, 2010
25792010
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
19372012
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
16202011
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell reports 19 (6), 1189-1201, 2017
15952017
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
M Krauthammer, Y Kong, BH Ha, P Evans, A Bacchiocchi, JP McCusker, ...
Nature genetics 44 (9), 1006-1014, 2012
13162012
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
11902012
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
11552017
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
10412014
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 724, 2012
8072012
A Smad transcriptional corepressor
D Wotton, RS Lo, S Lee, J Massagué
Cell 97 (1), 29-39, 1999
7131999
A structural basis for mutational inactivation of the tumour suppressor Smad4
Y Shi, A Hata, RS Lo, J Massagué, NP Pavletich
Nature 388 (6637), 87-93, 1997
6421997
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 5712, 2014
6302014
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
6032015
Determinants of specificity in TGF-β signal transduction
YG Chen, A Hata, RS Lo, D Wotton, Y Shi, N Pavletich, J Massagué
Genes & development 12 (14), 2144-2152, 1998
5011998
Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4
A Hata, RS Lo, D Wotton, G Lagna, J Massagué
Nature 388 (6637), 82-87, 1997
4971997
Therapy-induced tumour secretomes promote resistance and tumour progression
AC Obenauf, Y Zou, AL Ji, S Vanharanta, W Shu, H Shi, X Kong, ...
Nature 520 (7547), 368-372, 2015
4812015
Ubiquitin-dependent degradation of TGF-β-activated Smad2
RS Lo, J Massagué
Nature cell biology 1 (8), 472-478, 1999
4791999
The system can't perform the operation now. Try again later.
Articles 1–20